
MECLIZINE HYDROCHLORIDE- meclizine hydrocloride tablet Proficient Rx LP

H₂O

MECLIZINE HYDROCHLORIDE TABLETS, USP Rx only

DESCRIPTION

Chemically, Meclizine HCl is $1-(p-chloro-\alpha-phenylbenzyl)-4-(m-methylbenzyl)$ piperazine dihydrochloride monohydrate.



 $C_{25}H_{27}CIN_2$. 2HCI.

M.W. 481.88

Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).

CLINICAL PHARMACOLOGY

Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

INDICATIONS AND USAGE

For the management of nausea and vomiting, and dizziness associated with motion sickness.

CONTRAINDICATIONS

Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug.

Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.

PRECAUTIONS

PREGNANCY, Teratogenic Effects

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that medicine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

Pediatric Use

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

ADVERSE REACTIONS

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION

Motion Sickness

The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

HOW SUPPLIED

Meclizine HCI Tablets, USP are available in the following strengths and package sizes:

25 mg (Yellow, oval-shaped, scored, debossed with TL121)

Bottles of 10 NDC 63187-996-10Bottles of 20NDC 63187-996-20Bottles of 30NDC 63187-996-30

Bottles of 60 NDC 63187-996-60

Bottles of 90 NDC 63187-996-90

Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature].

Manufactured By:

Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA.

Repackaged by:

Proficient Rx LP

Thousand Oaks, CA 91320

Revised 03/11

PRINCIPAL DISPLAY PANEL



NDC 63187-996-20

Meclizine Hydrochloride Tablets, USP

25 mg

20 Tablets

Rx Only

DOSAGE AND USE

See accompanying prescribing information

MOTION SICKNESS:

25 mg to 50 mg daily.

Dispense in tight, light-resistant containers (USP).

Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature].

meclizine hydroclor	ide tablet							
Product Informa	ation							
Product Type		HUMAN PRESCRI DRUG	PTION	ltem Code (Source)	NDC:6 121)	3187-996(N	DC:59746-	
Route of Administ	ration	ORAL						
Active Ingredien	t/Active	Moiety						
Ingredient Name Basis of St							Strengt	
Meclizine Hydrochlo	-		clizine - UNII	:3L5TQ84570)	Meclizine Hyd	-	-	
Inactive Ingredie	ents							
	St	Strength						
Silicon Dioxide (UNII:	ETJ7Z6XBU4)						
Croscarmellose Sodium (UNII: M28OL1HH48)								
Lactose Monohydrate (UNII: EWQ57Q8I5X)								
Magnesium Stearate	e (UNII: 70097	7M6I30)						
MICROCRYSTALLINE			51U)					
D&c Yellow No. 10 (U								
Aluminum Oxide (UNI	I: LMI260693	3)						
Product Charact	eristics							
Color	YELL	ow	Score			2 pieces		
Shape	OVAL	Size			13mm			
Flavor		Imprint Code TL121						
Contains								
Packaging								
		Package Description			ing Start	Marke		

Μ	larketing l Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
M	larketing l	mormation				
	Marketing Information					
5	NDC:63187-996- 90	90 in 1 BOTTLE; Type 0: Not a Combination Product	06/17/2022			
4	NDC:63187-996- 60	0 in 1 BOTTLE; Type 0: Not a Combination 06/17/2022				
3	NDC:63187-996- 30	0 in 1 BOTTLE; Type 0: Not a Combination 01/01/2019 roduct				
2	NDC:63187-996- 20	20 in 1 BOTTLE; Type 0: Not a Combination Product	ot a Combination 03/01/2018			
	10	Product	05/12/2020			

Labeler - Proficient Rx LP (079196022)

Establishment							
Name	Address	ID/FEI	Business Operations				
Proficient Rx LP		079196022	REPACK(63187-996), RELABEL(63187-996)				

Revised: 6/2022

Proficient Rx LP